Skip to main content

Advertisement

SpringerLink
Log in

Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Prediagnosis obesity and diabetes are associated with survival from pancreatic cancer, but the underlying mechanisms have not been characterized. Because both are associated with dysregulation in circulating insulin-like growth factor (IGF) levels, we evaluated the associations of prediagnosis IGF levels (IGF-I, IGF-II) and IGF binding protein 3 (IGFBP-3) with pancreatic cancer survival.

Methods

Participants were subjects enrolled in the intervention arm of the PLCO Cancer Screening Trial who developed exocrine pancreatic cancer during follow-up (N = 178, 116 men and 67 women). Participants provided blood samples at enrollment, before cancer diagnosis. Cox proportional hazards regression model, adjusted for confounders was used to investigate associations of IGF biomarkers with pancreatic cancer survival. Because of the well-documented, gender-specific differences in circulating IGF biomarkers, and differential associations of IGF biomarkers with mortality, we evaluated associations separately among males and females.

Results

Median survival was 172 days. Higher IGF-II and IGFBP-3 levels were associated with pancreatic cancer survival among males but not among females. The hazard ratios (HR) of death among men in the highest tertiles of IGF-II and IGFBP-3 compared with men in the lowest tertiles were 0.40 (95% confidence interval (CI) 0.23–0.71, p < 0.01) and 0.59 (95% CI 0.35–0.97, p = 0.10), respectively. There were no statistically significant associations between IGF-I concentrations, IGF-I/IGFBP-3, and pancreatic cancer survival.

Conclusions

Higher prediagnosis circulating IGF-II and IGFBP-3 levels are associated with better pancreatic cancer survival among men but not women. A greater understanding of how IGF signaling is related to pancreatic cancer survival could have utility in improving pancreatic cancer prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–48.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Klein AP, Lindstrom S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, et al. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PloS One. 2013;8:e72311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Toriola AT, Stolzenberg-Solomon R, Dalidowitz L, Linehan D, Colditz G. Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer. 2014;111:181–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–69.

    CAS  PubMed  Google Scholar 

  5. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–46.

    Article  CAS  PubMed  Google Scholar 

  6. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Rev. 2000;21:215–44.

    Article  CAS  Google Scholar 

  7. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14:329–41.

    Article  CAS  PubMed  Google Scholar 

  8. Lashinger LM, Malone LM, McArthur MJ, Goldberg JA, Daniels EA, Pavone A, et al. Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxygenase-2-driven pancreatic neoplasia. Cancer Prev Res. 2011;4:1030–40.

    Article  CAS  Google Scholar 

  9. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2010;19:2298–306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rohrmann S, Grote VA, Becker S, Rinaldi S, Tjonneland A, Roswall N, et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2012;106:1004–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomark Prev. 2004;13:438–44.

    CAS  PubMed  Google Scholar 

  12. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, et al. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer. 2007;97:98–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.

    Article  CAS  PubMed  Google Scholar 

  14. Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, et al. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3 K/Akt signaling pathway in pancreatic cancer cells. J Surg Res. 2010;160:90–101.

    Article  CAS  PubMed  Google Scholar 

  15. Brabant G, von Zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, et al. (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60:53–60.

    CAS  PubMed  Google Scholar 

  16. Brabant G, Wallaschofski H. Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary. 2007;10:129–33.

    Article  CAS  PubMed  Google Scholar 

  17. Hietaniemi M, Pöykkö SM, Ukkola O, Päivänsalo M, Antero Kesäniemi Y. IGF‐I concentrations are positively associated with carotid artery atherosclerosis in women. Ann Med. 2005;37:373–82.

    Article  CAS  PubMed  Google Scholar 

  18. Undén A-L, Elofsson S, Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clin Endocrinol. 2005;63:94–102.

    Article  Google Scholar 

  19. Friedrich N, Haring R, Nauck M, Ludemann J, Rosskopf D, Spilcke-Liss E, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009;94:1732–39.

    Article  CAS  PubMed  Google Scholar 

  20. Friedrich N, Schneider H, Dorr M, Nauck M, Volzke H, Klotsche J, et al. All-cause mortality and serum insulin-like growth factor I in primary care patients. Growth Horm IGF Res. 2011;21:102–06.

    Article  CAS  Google Scholar 

  21. Zhu CS, Pinsky PF, Kramer BS, Prorok PC, Purdue MP, Berg CD, et al. (2013) The Prostate, lung, colorectal, and ovarian cancer screening Trial and its associated research resource. J Natl Cancer Inst 105(22):1684–93.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Oaks BM, Dodd KW, Meinhold CL, Jiao L, Church TR, Stolzenberg-Solomon RZ. Folate intake, post-folic acid grain fortification, and pancreatic cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Clin Nutr. 2010;91:449–55.

    Article  CAS  PubMed  Google Scholar 

  23. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 2010;95:1717–25.

    Article  CAS  PubMed  Google Scholar 

  24. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, et al. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008;14:8263–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Harris LK, Westwood M. Biology and significance of signalling pathways activated by IGF-II. Growth Factors. 2012;30:1–12.

    Article  CAS  PubMed  Google Scholar 

  26. O’Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology. 2002;143:4287–94.

    Article  PubMed  Google Scholar 

  27. Chang S, Wu X, Yu H, Spitz MR. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomark Prev. 2002;11:758–66.

    CAS  Google Scholar 

  28. Young NJ, Metcalfe C, Gunnell D, Rowlands MA, Lane JA, Gilbert R, et al. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. Cancer Causes Control. 2012;23:907–17.

    Article  PubMed  Google Scholar 

  29. Florini JR, Magri KA, Ewton DZ, James PL, Grindstaff K, Rotwein PS. “Spontaneous” differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J Biol Chem. 1991;266:15917–23.

    CAS  PubMed  Google Scholar 

  30. Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, et al. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014;5:307–13.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20:1193–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Clemmons DR. Insulin-like growth factor binding protein control secretion and mechanisms of action. Adv Exp Med Biol. 1991;293:113–23.

    Article  CAS  PubMed  Google Scholar 

  33. Ho KK, Gibney J, Johannsson G, Wolthers T. Regulating of growth hormone sensitivity by sex steroids: implications for therapy. Fron Horm Res. 2006;35:115–28.

    CAS  Google Scholar 

  34. Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T, et al. Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer. 2004;110:584–88.

    Article  CAS  PubMed  Google Scholar 

  35. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009;27:176–85.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Haydon AM, Macinnis RJ, English DR, Morris H, Giles GG. Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Int J Gastroenterol Hepatol. 2006;55:689–94.

    CAS  Google Scholar 

  37. Svensson J, Carlzon D, Petzold M, Karlsson MK, Ljunggren Ö, Tivesten Å, et al. Both low and high serum IGF-I levels associate with cancer mortality in older men. J Clin Endocrinol Metab. 2012;97:4623–30.

    Article  CAS  PubMed  Google Scholar 

  38. Major JM, Laughlin GA, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Insulin-like growth factor-I and cancer mortality in older men. J Clin Endocrinol Metab. 2010;95:1054–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol. 2007;166:518-26.

    Article  PubMed  Google Scholar 

  40. Van Bunderen CC, Van Nieuwpoort IC, Van Schoor NM, Deeg DJH, Lips P, Drent ML (2010) The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab 95:4616–24.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

Adetunji T. Toriola is supported by the Siteman Cancer Center, Barnes-Jewish Hospital Foundation and Washington University School of Medicine Faculty Diversity Award. The funding sources have no roles in the study design, collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.

Disclosure

The authors declare no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Public Health Sciences, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA

    Adetunji T. Toriola MD, PhD, MPH, Mark Ziegler MS & Yize Li MS

  2. Department of Oncology, McGill University, Montreal, Canada

    Michael Pollak MD

  3. Branch of Nutritional Epidemiology, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, MD, USA

    Rachael Stolzenberg-Solomon PhD, MPH, RD

Authors
  1. Adetunji T. Toriola MD, PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Ziegler MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yize Li MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Pollak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachael Stolzenberg-Solomon PhD, MPH, RD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adetunji T. Toriola MD, PhD, MPH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toriola, A.T., Ziegler, M., Li, Y. et al. Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. Ann Surg Oncol 24, 3212–3219 (2017). https://doi.org/10.1245/s10434-017-5988-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-5988-y

Keywords

Search

Navigation